All In Biotech

Drug Trial Radar · NCT03095456

Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD

A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR

Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 207 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

207

Actual

Start

Mar 27, 2017

Primary completion

Nov 25, 2017

Study completion Nov 25, 2017

Sponsor

Lead sponsor
Mylan Inc.Industry
Sponsor type
Industry
Collaborators
Theravance Biopharma
First posted
Mar 29, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak Inspiratory Flow Rate.

Conditions

  • Chronic Obstructive Pulmonary Disease, COPD
  • Low Peak Inspiratory Flow Rate (PIFR)

Interventions

  • RevefenacinDrug

    Revefenacin administered via nebulization.

  • Spiriva Handihaler®Combination product

    Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.

  • Placebo for RevefenacinDrug

    Placebo administered as double blind, double dummy via nebulization.

  • Placebo for Spiriva Handihaler®Drug

    Placebo administered as double blind, double dummy via Spiriva HandiHaler®.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trough FEV1 on Day 29Time frame: Baseline and Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Research of Rock Hill

    Rock Hill, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.